Taipei Veterans General Hospital Practices Guidelines Oncology

Head and Neck Cancers

Cancer of Nasopharynx

Version 2022
Proofing at NPC MDT Conference on 202207__

Table of Content

- Taipei VGH NPC Panel Members
- Principles for Guidelines Revision
- Summary of Guidelines Updates
- Pathology
- Multidisciplinary NPC Team
- Pretreatment Workup
  - MRI protocol for NPC
- TNM staging
  - Summary of change in 8th TNM Stage
  - Taipei VGH supplement to TNM staging
  - Table of stage grouping
  - Taipei VGH risk group modification
  - Table of Taipei VGH risk group
- **Management by Risk Groups**
  - Low risk groups: A, B
  - High risk groups: C, D
  - Metastatic disease and Group E
- Summary table for management by risk groups
- Management of residual disease after radiation therapy
- Management of locoregional recurrence
- Principles of radiation therapy
- **Charged Particle Therapy**
- Principles of chemotherapy
- Follow-up
- Acronym
- Manuscript
- NPC Survival Data and Survival Curves of at Taipei VGH
- References

Taipei VGH Nasopharyngeal Cancer Panel Members

- **Radiation Oncology**
  - 蕭正英*；王令瑋；黃品逸；胡育文
- **Otorhinolaryngology/Head and Neck Surgical Oncology**
  - 藍敏瑛；趙匀廷； 葉建甫；洪莉婷；許志宏
- **Medical Oncology**
  - 楊慕華；張牧新；陳天華
- **Diagnostic Radiology**
  - 凌憬峰*；陳書庭
- **Nuclear Medicine**
  - 郭昱
- **Pathology**
  - 郭盈汝
- **Cancer Case Manager**
  - 簡伶怡

* Writing Committee Member

Principles for Guideline Revision

- **This guideline is conformed to evidence-based medicine and/or complied with the currently consented practices.**
- **This guideline is systemically reviewed in an annual guideline revision meeting within the NPC multidisciplinary conference.**
- **This guideline is based on consensus of the authors regarding the current evidence for appropriate approaches to workup and treatment.**
- **Any physician consulting this guideline is expected to use independent medical judgment of individual clinical circumstances to determine and apply optimal customized treatment for the cancer patient.**

Summary of Guidelines Updates vs 2021

- **Discussion of Proton Therapy, Carbon Ion Therapy and BNCT in Principles of Radiation Therapy**
- **Update of NPC 2010~7 overall survival and cancer-specific survival data**
- **Review of NCCN guidelines 2022 vs 2021**
  - No major revision that are not encompassed by the VGH Guidelines
  - Recommendation of RT alone for T1-2 N0 disease, aligned with the recommendation of VGH guidelines for VGH risk group A since 2007
  - Removal of the recommendations of Clinical Trials for N+ or T3~4 disease, which was never the recommendation of Taipei VGH
  - Revision of recommendations for M1 disease: Systemic therapy followed by CCRT for oligometastases or CR after systemic therapy, same as Taipei VGH Guideline.
  - ***Adjuvant one-year low-dose Capecitabine for T4 or N2-3 M0***
  - Palliative QUAD SHOT regimen: 44.4Gy, delivered in 12 fractions over three cycles, with each cycle separated by 2 to 3 weeks
  - RT should not be used concurrently with BRAF/MEK inhibitor therapy (H&N Mucosal Melanoma), as concurrent use has been found to be associated with grade ≥3 dermatologic reactions, and potentially lethal hemorrhaging in the liver, lung, and brain have all been reported.

Multidisciplinary Team

- **Radiation Oncology**
  - Radiation Oncologist; Radiation Physicist; Radiation Technologist
- **Medical Oncology**
- **Surgical Oncology specialized in Head and Neck Cancers**
  - Otorhinolaryngology (ENT)
- **Pathology**
- **Diagnostic Radiology**
- **Nuclear Medicine**
- **Case Manager**
- **Dentistry/Prosthodontics**
- **Clinical Pharmacology**
- **Social Workers**
- **Nutritional Support**

Pathology

This practice guideline is applicable only for keratinizing and non-keratinizing carcinoma of nasopharynx as specified in the WHO classification. Other uncommon malignant tumor should be managed according to their histopathological diagnosis. The pathological specimen is preferably obtained from biopsy of nasopharynx.

- **Pathology: WHO 2005 classification (1991)**
  - Type I: Keratinizing Carcinoma
    - ICD-O3 Morphological code: M8071/3
  - Type II: Non-Keratinizing Carcinoma
    - II-a: Differentiated (WHO 1987 classification non-keratinizing carcinoma) ICD-O3 Morphological code: **M8072/33**
    - II-b: Undifferentiated (WHO 1987 classification undifferentiated carcinoma) ICD-O3 Morphological code: **M8072/34**
    - Basaloid Squamous Cell Carcinoma: **M8083/3**
- **Other uncommon malignant tumors of nasopharynx**
  - Adenoid cystic carcinoma: pay special attention to peri-neural spreading in target volume delineation during radiation therapy planning..
  - Lymphoma: see practice guidelines of Non-Hodgkin's Lymphoma and Hodgkin's Disease.
  - Plasmacytoma: see practice guidelines of multiple myeloma.

Pretreatment Workup

- **General medical history and physical examination**

Imaging Studies

- **MRI of Nasopharynx and whole neck (see MRI Protocol for NPC)**
- **CT of nasopharynx only if MRI is contraindicated.**
- **PET-CT or PET-MR**
  - Recommended for N2/3 or stage III/IV)
  - **Recommended for low stage group but high serum EBV cDNA**
- **CT Chest (from supraclavicular fossa to liver)**
- **Chest X-ray, if no CT Chest**
- **Liver sonogram, if no CT Chest**
- **Bone scan for stage II-IV, optional for stage I; optional if PET/CT performed**
- **Sonography for equivocal neck lymphadenopathy**

Serum Tests

- **CBC**
- **Serum EBV cDNA (EBV PCR)**
- **Complete serum metabolite analyses, including liver/renal function test and LDH**
- **Hepatitis B and C markers, and CCr if chemotherapy is indicated**
- **Baseline thyroid function (optional)**
- **Baseline pituitary function if unavoidable high radiation dose to pituitary gland in T4 case. (optional)**

Special Exams

- **Audiometry**
- **Ophthalmologic exams if at high risk of radiation injury to optic nerve**
- **Baseline salivary function test or salivary scintigraphy**
- **Pre-radiotherapy dental care**
- **Olfactory test**

MRI Protocol for Nasopharyngeal Cancer

- **Five series:**
  - Spin-Echo Axial T1
  - Spin-Echo Axial T2
  - Spin-Echo Axial T1 + Contrast + Fat Saturation
  - Spin-Echo Coronal T1 + Contrast + Fat Saturation
  - Spin-Echo Sagittal T1 + Contrast
- **Volume:**
  - From frontal sinus down to supraclavicular fossa
  - 3-5 mm slide thickness

TNM Staging System: UICC/AJCC 2017 8th Edition

T category

TX	Primary tumor cannot be assessed
T0	No primary tumor identified, but EBV positive cervical node(s) involvement
T1	Tumor confined to the nasopharynx; or extending to oropharynx and/or nasal cavities without parapharyngeal extension
T2	Tumor with extension to **parapharyngeal space** and/or **adjacent muscle involvement** (**medial pterygoid, lateral pterygoid, prevertebral muscles**)
T3	Tumor with infiltration of bony structures at skull base, cervical vertebra, pterygoid structures, and/or paranasal sinuses
T4	Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, **parotid gland**, and/or **extensive soft tissue infiltration beyond the lateral surface of pterygoid muscles**

Parapharyngeal space (PPS) - a triangular space:

- Anterior to the styloid process (prestyloid space)
- From the skull base to the level of the mandibular angle
- Lateral to the pharynx and medial to the masticator / parotid spaces

N category

Nx	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Unilateral metastasis in cervical lymph node(s); and / or unilateral / bilateral retropharyngeal nodes; all ≤6 cm and above the caudal border of cricoid cartilage
N2	Bilateral metastases in cervical node(s), all ≤6 cm and above the caudal border of cricoid cartilage
N3	Metastasis in cervical node(s) >6cm and/or **extension below the caudal border of cricoid cartilage (Level IV)**

M category

N0	No distant metastasis
N1	Distant Metastasis

Summary of Changes in AJCC 8th TNM for NPC

Change	Details of Change
Definition of T0	• T0 is added for Epstein-Barr virus (EBV) positive unknown primary with cervical lymph node involvement. The stage group is defined in the same way as T1(or TX).
Definition of T2 by muscle involvement	• Adjacent muscles involvement (including medial pterygoid, lateral pterygoid, and prevertebral muscles) is now designated as T2.
Definition of T4	• The previous T4 criteria "masticator space" and "Infratemporal fossa" is now replaced by specific description of soft tissue involvement to avoid ambiguity. • Parotid gland involvement is specifically classified as T4.
Definition of N3 by lymphatic station	• The previous N3b criterion of supraclavicular fossa is now changed to lower neck (as defined by nodal extension below the caudal border of the cricoid cartilage, level IV).
Merge of N3	• N3a and N3b are merged into a single N3 category, which is now defined as unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage.
AJCC Stage Group IVA	• The 7th Sub-Stages IVA (T4 N0-2 M0) and IVB (any T, N3, M0) are now merged to IVA
AJCC Stage Group IVB	• The 7th Sub-Stage IVC (any T, any N, M1) are now designated as IVB

Summary of Changes: From 6th to7Th TNM System

- **The T2a category of the 6th TNM stage, invasion to soft tissues of oropharynx and/or nasal cavity only without parapharyngeal space extension, is designated as T1 in the 7Th TNM stage. Therefore, the 6th TNM Stage IIA (T2aN0M0) and Stage IIB (T2bN0M0) will now be Stage I and Stage II, respectively, in the 7th TNM Stage,**
- **Retropharyngeal lymph node(s), regardless of unilateral and bilateral, is staged as N1 in the 7th TNM stage.**
  - Combined retropharyngeal lymphadenopathy and unilateral neck lymphadenopathy is classified as N1.
- **There is no clinical Mx classification (cMx) and no pathological M0 classification (pM0).**
  - The only evaluation necessary to classify as clinically M0 is history and physical examination.
  - Negative biopsy of a suspected lesion does not completely rule out a missed biopsy or other elsewhere occult distant metastases.

TNM Staging System: UICC/AJCC 2017 8th Edition
Taipei VGH Supplement

T category

- **Cavernous sinus and/or dura invasion should be classified as T4.**
- **Pterygopalatine fossa invasion should be classified as T3.**
- **There is a big jump of T category from T1 for oropharyngeal invasion to T4 of hypopharyngeal invasion.**
- **There is also a jump of T category from T2 of adjacent muscle invasion to T4 of infiltration beyond the lateral surface of pterygoid muscles**
- **T1/T2 with *T>6cm* should be documented for risk grouping.**
- **T3 with anterior ethmoid extension between eyeballs should be documented for risk grouping.**

Imaging Criteria for Lymphadenopathy (LAP)

- **Pathological features**
  - Central necrosis
  - Extranodal Extension (ENE)
- **Size (maximum diameter)**
  - Level I and IIa (jugulodigastric node) >1.5cm
  - Retropharyngeal LAP > 5mm
  - Other regions (including IIb) > 1cm
- **Imaging features favoring pathological LAP**
  - Group of 3 contiguous lymph nodes with diameter ≥8mm.
  - Long-Short Axis Ratio <2
- **Imaging features favoring benign/reactive lymph node**
  - Intact hilum
  - Long-Short Axis Ratio ≥2

N category

- **The N staging method should include at least CT and/or MRI.**
- **The size of lymphadenopathy (LAP) should be measured by CT and/or MRI, and not by palpation/inspection.**
- **The diameter of LAP should be the sum of multiple contiguous confluent LAP.**
- **The size of the largest individual LAP should be documented for risk grouping.**
- **The level of LAP should be documented for risk grouping.**
- **Level 4/5b LAP at T1 transverse process or below or below the transverse vein of neck should be classified as supraclavicular LAP.**
- **Level Ib and pre-auricular/peri-parotid LAP should be documented for risk grouping.**
- **Level VII Superior Mediastinal (including pretracheal, paratracheal, and esophageal groove LNs, extending from the level of the suprasternal notch cephalad and up to the innominate artery caudad. Level VII is considered as regional nodes in other head and neck cancers but is classified as distant metastasis in NPC.**

TNM Staging System: UICC/AJCC 2017 8th Edition
Stage Grouping of M0 Disease (M1 disease as Stage IVb)

	T0	T1	T2	T3	T4
N0		I	II	III	IVa
N1	II	II	II	III	IVa
N2	III	III	III	III	IVa
N3	IVa	IVa	IVa	IVa	IVa

Taipei VGH Risk Group for Nasopharyngeal Cancer
T and N Modification

T category Modification

- **Bulky T1~2 with diameter > 6cm should be treated as T3.**
- **T2 disease with >1/2 pterygoid muscle invasion should be treated as T3**
- **Bulky T3 with anterior ethmoidal extension between eyeballs should be treated as T4.**

N category Modification

- **N1 with the following high risk features should be treated as N2.**
  - Level I-b LAP
  - Pre-auricular or peri-parotid LAP
  - Level III/Va LAP
  - Any individual LAP > 3cm (bulky N1)

Taipei VGH Risk Group Mapping Table for NPC

M0	Non-Bulky T1 ≤ 6 cm or T0	Non-Bulky T2 ≤ 6 cm	Non-Bulky T3 or Bulky T1-2 >6cm, T2 > ½ pterygoid muscle invasion	T4 or Bulky T3 (anterior ethmoid extension)
N0	A	A	B	C
Low Risk N1 (level II & LAP ≤ 3cm)	B	B	B	C
N2 or High Risk N1 (level Ib, preauricular, or III/Va, single LAP > 3cm)	D_1	D_1	D_1	D_1
N3 without Superior Mediastinal LAP	D_2	D_2	D_2	E
N3 with Superior Mediastinal LAP	E	E	E	E

Localized NPC: Low Risk Groups

Risk Group A

- **Definition**
  - Non-bulky T1/T2 (T<6cm) N0 M0
- **Treatment of Choice**
  - Radical radiation therapy alone
- **Alternative Treatment**
  - CCRT only

Risk Group B

- **Definition**
  - T1 or T2, and Non-bulky N1
  - Non-bulky T3, N0 or Non-bulky N1
- **Treatment of Choice**
  - CCRT only
- **Alternative Treatment**
  - Induction chemotherapy + CCRT
  - Radical radiotherapy alone

See T and N Modification for definition of bulky T and bulky N

Localized NPC: High Risk Groups

Risk Group C

- **Definition**
  - Bulky T3 or T4, N0 or Non-bulky N1
- **Treatment of Choice**
  - Induction C/T + CCRT
- **Alternative Treatment**
  - Induction C/T+ CCRT + adjuvant

Risk Group D1

- **Definition**
  - T1-4, N2 or Bulky N1 (D_1)
- **Treatment of Choice**
  - Induction C/T + CCRT + adjuvant
  - Induction chemotherapy + CCRT

Risk Group D2 and E

- **Definition**
  - T1-3, N3 (D_2)
  - T4N3 or TxN3 with superior mediastinal LAP (E)
- **Treatment of Choice**
  - Induction C/T + CCRT + adjuvant
- **Alternative Treatment**
  - Induction C/T + CCRT
  - CCRT only
- **Clinical Trial/Research Protocol**
  - Enrollment to clinical trial, especially for stage IV (D_2) patients

See T and N Modification for definition of bulky T and bulky N

Management of Metastatic NPC

- **Enrollment to clinical trial is encouraged.**
- **Systemic chemotherapy is the mainstay of treatment.**
  - At least 4-6 cycles of systemic chemotherapy.
  - Response evaluation should be done after the 2nd or 3rd cycles of systemic chemotherapy.
  - Targeted therapy, such as Cetuximab, as second line therapy.
- **Palliative RT**
  - Early administration of palliative RT for symptomatic weight-bearing bone metastases, brain metastasis, and metastatic lesions causing spinal cord compression, obstructive jaundice/obstructive pneumonitis.
  - Delayed administration of palliative RT for asymptomatic metastatic lesions
- **RT for locoregional disease of M1 NPC**
  - If radiotherapy is to be given to the locoreginal disease, it could be performed after the 4th cycle of systemic chemotherapy.
  - See Principles of RT for M1 NPC

Treatment Alternatives by Taipei VGH Risk Groups for NPC
Summary Table

	A	B	C	D1	D2	E /M1
RT Only 放射治療	1	3	-	-	-	-
CCRT only 同步藥物放射治療	2	1	-	-	-	-
Induction + CCRT 導引藥物 + 同步藥物放射治療	-	2	1	1	2	-
Induction + CCRT + Adjuvant 導引藥物 + 同步藥物放射治療 + 輔助藥物	-	-	2	1	1	-
Systemic chemotherapy 藥物治療為主 ± CCRT or RT	-	-	-	-	-	1

The numbers in the table represent the priority of treatment alternatives for each risk group with 1 being the treatment of choice. For patient with age > 70 or low performance status (KPS < 70 or ECOG 3), the treatment intensity should be reduced at the discretion of attending physician.

Management of Residual Tumors/Lymphadenopathy

- At the discretion of radiation oncologist, a boost dose, 10Gy in 5 fraction or less, can be given to residual tumor / lymphadenopathy found at the end of standard dose 70Gy.
- Biopsy of residual primary tumor and/or lymphadenopathy should be done after an observation period of 12 weeks after the completion of RT.
- Once residual disease is confirmed, PET scan and MRI should be done for planning of salvage treatment.
- Salvage operation could be considered for operable residual disease.
- Radical neck dissection is the preferred salvage treatment for residual lymphadenopathy
- Re-irradiation of residual disease is indicated when surgical margin is positive or salvage surgery is not feasible.

Management of Locoregional Recurrence

- **Tissue proof of locoregional recurrence should be obtained.**
- **Once locoregional recurrence is confirmed, PET scan and MRI should be done for planning of salvage treatment.**
- **For in-field recurrent NPC**
  - Salvage endoscopic nasopharyngectomy would be feasible for recurrent NPC in nasopharynx, paranasopharyngeal space, parapharyngeal space, paranasal sinuses, infratemporal fossa without intracranial extension to the cavernous sinus.
  - Re-irradiation is indicated when surgical margin is positive or salvage surgery is not feasible.
  - Post-operative chemotherapy may be indicated.
- **For recurrent NPC in anterior marginal miss**
  - Surgery is the treatment of choice if the tumor can be completely removed without the need of post-operative irradiation.
  - Re-irradiation would be the treatment of choice for radiosensitive tumor.
  - Surgery with or without post-operative radiotherapy is feasible for radioresistant tumor.
- **Selective neck dissection is the preferred salvage treatment for recurrent neck lymphadenopathy.**

Principles of Radiation Therapy

See Practice Guidelines of Radiation Therapy for general standard operating procedures, tolerance dose of critical normal structures, quality assurance, DVH criteria for plan approval, and etc.

- **Radiation therapy for newly diagnosed non-metastatic NPC**
- **Radiation Therapy for M1/Group E disease**
- **Re-irradiation of recurrent primary tumor and/or lymphadenopathy**

Principles of Radiation Therapy for Newly Diagnosed Non-Metastatic NPC

- **Delineation of Gross Target Volume**
  - Image fusion with MRI (See NPC MRI Protocol) and optional PET-CT for precise delineation of GTV, as defined in ICRU report 50 and 62)
- **Delineation Clinical Target Volume**
  - **CTV_H: GTV of primary tumor and neck lymphadenopathy (No extra margin)**
    - ***After induction CT, residual GTV***
  - CTV_M:

    Primary Tumor
    - Inclusion of whole nasopharynx:
      Superior skull base: 1cm above foramen lacerum, Foramen ovale
      Parapharyngel /retropharyngeal space and prevertebral muscle down to C1-2 junction,
      Pterygopalatine fossa, posterior wall of maxillary sinus
    - 2- (near critical structures) to 5-mm margins around (***pre-induction***) GTV for T2-T4 lesions
    - Inclusion of bilateral tonsils
    - Inclusion of whole clivus in case of clivus invasion

    Lymphatic region
    - Inclusion of level II for all N categories
    - Inclusion of one level below GTV of neck node
    - Level I-b irradiation can be excluded but should be included with gross level I-b lymphadenopathy and be considered to be included in the presence of large II-a (>3cm) lymphadenopathy.
    - Exclusion of non-invaded surrounding muscle
  - CTV_L:
    - Lymphatic region one level away from GTV of neck lymphadenopathy
    - **At least to level III for node negative side of neck**
- **Margins for Planning Target Volume**
  - 3 mm around primary tumor
  - 5 mm around neck lymphadenopathy
- **Radiation Dose**
  - CTV_H: **69.3-74 Gy in 33~37 fractions**
    Optional 66Gy/30 fractions for stage I & II disease with T1/non-bulky T2 and N0/non-bulky N1
  - **Optional BID 70~72Gy/56~60Fractions for T4 disease**
  - CTV_HM (Optional): an intermediate dose of 63-66 Gy in 30- 35 fractions to small volume lymph nodes in close proximity to critical structures
  - CTV_M: 57Gy-63Gy in 30-35 fractions
  - CTV_L: 45-54Gy/25-33 fractions or 56Gy/35 fractions
  - Boost dose, up to a maximal total dose of 80Gy, to residual tumor / lymphadenopathy at the discretion of radiation oncologist.
  - CTV of unplanned neck lymph node biopsy / dissection with negative margin: 59.4Gy-63Gy in 30-35 fractions
  - CTV of unplanned neck lymph node biopsy / dissection with positive margin: 65 Gy at least
- **Radiation Technique**
  - Intensity Modulated Radiation Therapy (IMRT) with simultaneous integrated boost (SIB)
- **Timing of Radiation Therapy**

  Radiotherapy alone:
  Within 2 weeks after the completion of staging procedures or as soon as healing of the teeth extraction wound.

  Following induction / neoadjuvant chemotherapy
  Within 4 weeks after the start of the last cycle of induction chemotherapy

Radiation Therapy for Metastatic NPC or Locoregional Recurrence

RT for Metastatic NPC

- **Locogegional irradiation for M1 disease**
  - Given after 3-4 cycles of systemic chemotherapy
  - Optionally, 10% reduction from the standard dose along with concurrent chemotherapy
- **Palliative RT for metastatic site**
  - 30-50 Gy in 12-25 fractions to metastatic lesions, if indicated.
  - Aggressive RT for oligometastases could be considered for good responders.

RT for Locoregional Recurrence

**If salvage surgery is not feasible for the recurrent disease, or positive margins is found after salvage surgery,
re-irradiation could be done with the following principles:**

- **Target volume**
  - Recurrent GTV with minimal but adequate margin
- **Radiation Dose**
  - 60Gy in 5-6 weeks
- **Fractionation**
  - Conventional QD fractionation 60Gy in 30 fractions, or
  - Hyperfractionated RT 60 Gy in 50 fractions
- **Concurrent chemotherapy, if not contraindicated**

Critical Structures and Radiation Tolerance Tolerance Dose

Normal Tissue	Ideal Criteria	Acceptable Criteria
Brain Stem	<54Gy	1ml or less < 60Gy
Spinal Cord	<45Gy	1ml or less < 50Gy
Parotid Gland	mean < 26Gy	mean dose < 35Gy
Optic nerve	<50Gy	<56Gy
Lens	< 6Gy	<10Gy
Inner Ear	<50Gy; mean < 45Gy	-
Temporal Lobe	< 56Gy	1% < 63Gy
PTV_H dose limit	V107 of PTV_H<10%	V107 of PTV_H<20%

Principles of Chemotherapy

- The regimens and dose intensity are similar for systemic chemotherapy for M1 NPC, induction chemotherapy and adjuvant chemotherapy.
- The regimens and dose intensity of chemotherapy for concurrent chemotherapy is generally altered or reduced to decrease the severity of mucositis.
- Performance status and age of patient should be factored in the incorporation and administration of chemotherapy.
- Other drugs combined with cisplatin such as paclitaxel, tegafur/uracil, mitomycin, epirubicin, etc. could be considered according to the specific patients' condition with consensus reached in the combined conference
- Carboplatin should only be considered unless patient's CCr < 40 or other inevitable reasons that cisplatin cannot be used.
- Cetuximab could be added according to the physician's judgments
- In recent published studies, CCRT alone is found to be inferior to either induction chemotherapy + CCRT or CCRT + adjuvant chemotherapy for Stage III or Stage IV A-B Nasopharyngeal cancer.

Induction Chemotherapy

- The induction chemotherapy should be limited Q3W *2 or Q2W *3, if there is planned adjuvant chemotherapy after CCRT. It could increased to Q3W *3 or Q2W*4 in case of no further adjuvant chemotherapy.
- For large T4 NPC with high risk of radiation injury to optic nerve, brain stem and/or spinal cord, 9-12 weeks of induction chemotherapy could be given to reduce tumor bulk in order to reduce the probability of radiation injury.
- Response to induction chemotherapy should be well documented.

Adjuvant Chemotherapy

- Adjuvant chemotherapy should be performed within 8 weeks after the completion of radiation therapy.
- If less than partial response after the induction chemotherapy is observed, a change of adjuvant regimen, such as adding cetuximab targeted therapy, should be considered.
- The number of cycle of adjuvant chemotherapy is usually 3 for Q3W/Q4W regimens or 6 for Q2W regimens.

Regimens of Induction/Adjuvant/Systemic Chemotherapy

- **4-day PFL (Q3W)**
  - Cisplatin 80 mg/m^2 infusion for 3 hour
  - 5-FU: 600 mg/m^2 per 24 hours as a 96 hour continuous infusion
  - Leucovorin 90 mg/m^2 per 24 hours as a 96 hour continuous infusion
- **PCF (Q3W)**
  - Paclitaxel 135 mg/m^2 infusion for 3 hours on Day 1
  - Cisplatin 75 mg/m^2 infusion for 3 hours on Day 1
  - 5-FU: 600 mg/m^2 per 24 hours as a 96-hour continuous infusion
- **TPF (Q3W)**
  - Docetaxel 60 mg/m^2 infusion for 3 hours
  - Cisplatin 75 mg/m^2 infusion for 3 hours
  - 5-FU: 850 mg/m^2 per 24 hours as a 96-hour continuous infusion
- **Cisplatin + De Gramont (Q2W)**
  - Cisplatin 50 mg/m^2 infusion for 3 hours
  - Leucovorin 200 mg/m2 infusion for 2 hours per day for 2 days
  - 5-FU 400 mg/m^2 infusion for 30 minutes per day for 2 days
  - 5-FU 600 mg/m^2 per 24 hours as a 48-hour continuous infusion
- **PMU (Q4W)**
  - Cisplatin 70 mg/m^2 infusion for 3 hours
  - Mitomycin C 7 mg/m^2 infusion for 30 min.
  - Tegafur 100mg + Uracil 224 mg, PO TID, continuous
- **Gemcitabine + Cisplatin (Q3W)**
  - Gemcitabine 1gm/m^2 D1 & D8
  - Cisplatin 80mg/m^2 D1
- **Ufur (Optional)**
  - Tegafur 100mg + Uracil 224 mg, PO, 2# BID, as adjuvant treatment for 12 months

Chemotherapy Regimen for Concurrent Chemoradiotherapy

- **4-day PFL with reduced 5FU dose**
  - Cisplatin 80 mg/m^2 infusion for 3 hour
  - 5-FU: 400 mg/m^2 per 24 hours as a 96 hour continuous infusion
  - Leucovorin 90 mg/m^2 per 24 hours as a 96 hour continuous infusion
  - Total 2 cycles during RT, 4 weeks apart
- **PMU (PMuFur)**
  - Cisplatin: 70 mg/m^2 infusion for 3 hours
  - Mitomycin C: 7 mg/m^2 IV > 3-5 min
    - Total 2 cycles, 4 weeks apart
  - Tegafur 100mg + Uracil 224 mg, PO TID, through out RT
- **CFHX (Q3W) x 2 cycles**
  - Cisplatin 20mg/m^2 infusion for 4 hours
  - 5-FU 600mg/m^2 per 24 hours as a 96-hour continuous infusion
  - Hydroxyurea 500mg po stat and bid x11 doses
- **PT**
  - Cisplatin:60 mg/m^2 IV infusion for 3 hours, D2
  - Taxol:135 mg/m^2 IV infusion for 3 hours, D1
  - Total 2 cycles, 4 weeks apart
- **Weekly Cisplatin**
  - Cisplatin 30 mg/m^2 infusion for 3 hour QW Week 1 through Week 7 during RT
- **Weekly Cisplatin + Cetuximab (QW) x 7 cycles**
  - Cisplatin 30-35 mg/m^2 infusion for 3 hours
  - Cetuximab 400 mg/m^2 infusion for 2 hours at first cycle
  - Cetuximab 250 mg/m^2 infusion for 2 hours from 2nd cycle
- **Q3W Cisplatin**
  - Cisplatin 100 mg/m^2 infusion for 3 hour
  - Week 1, 4 and 7 during RT
- **Cetuximab (QW) x 7 cycles**
  - Reserved for patients unsuitable for cisplatin-based chemotherapy (?)
  - Cetuximab 400 mg/m^2 infusion for 2 hours at first cycle
  - Cetuximab 250 mg/m^2 infusion for 2 hours from 2nd cycle

Timing

- **The concurrent chemotherapy should start before the 6th fraction of radiotherapy.**

Follow-Up

- **If the patient develops of symptoms and signs for recurrent disease during the follow-up, the following studies may be arranged ahead of the fixed follow-up schedule.**
- **Physical examination and endoscopy**
  - 1st year: monthly
  - 2nd year: every 2 months
  - 3rd year: every 3 months
  - 4th year and thereafter: every 6 months
- **Timing of biopsy for residual disease**
  - 12 weeks after the completion of RT
- **MRI of nasopharynx**
  - 12 weeks after the completion of radiotherapy
  - 1 years after the start of treatment
  - Every 6 months for the 2^{nd} & 3^{rd} years
  - Once a year in the 4^{th} & 5^{th} years.
  - Once at the 7^{th} & 10^{th} years.
- **CXR**
  - Every 6 months in the first 3 years
  - Once a year thereafter
- **Liver Sonography**
  - Every 6 months in the first 3 years
  - Once a year thereafter
- Dopscan of carotid artery
  - Once a year
- **Bone scan**
  - Once a year for N3 disease
- **Serum EBV PCR**
  - After induction and just before CCRT
  - Within 4 weeks after the completion of CCRT
  - Within 4 weeks after the completion of adjuvant ST
  - Every 6 months in the first 5 years
- **Serum metabolite analysis for liver and renal function**
  - Every 3-6 months in the first 2 years
  - Every 6-12 months thereafter up to 5 years
- **Thyroid function test**
  - Once a year
- **Audiometry**
  - Once a year for 5 year
- **Dental care**
  - **Every 3-6 months**
- **Swallowing function**
  - Optional VFSS in the 5th year after radiotherapy
- **Salivary function**
  - Optional salivary function test at 1 year, 3 year and 5 year from start of radiotherapy
- **Quality of life**
  - Optional QOL survey at 1 year, 3 year and 5 year from start of treatment

Acronym

- **3D-CRT: 3D Conformal Radiation Therapy**
- **CCRT: Concurrent chemoradiotherapy**
- **CTV: Clinical Target Volume**
- **GTV: Gross Tumor Volume**
- **IGRT: Image Guided Radiation Therapy**
- **IMRT: Intensity Modulated Radiation Therapy**
- **MRI: Magnetic Resonance Image**
- **NPC: Nasopharyngeal Cancer**
- **PET: Positron Emission Tomography**
- **PTV: Planning Target Volume**
- **RT: Radiation Therapy**
- **WHO: World Health Organization**

Manuscript

Multidisciplinary team

The management of nasopharyngeal cancer is a joined effort of a specialized multidisciplinary oncological team (NPC multidisciplinary team), consisting of radiation oncologist, medical oncologist, head and neck surgical oncologist, pathologist, radiologist, radiation physicist, radiation technologist, dentist, oncological nurse and social workers.

Diagnosis, Tissue Proof and Histopathology

Definitive diagnosis of nasopharyngeal cancer (NPC) is made by endoscopic biopsy of the primary nasopharyngeal tumor, even though occasionally a NPC patient has incisional biopsy of neck lymphadenopathy prior to biopsy of the primary tumor. This practice guidelines are applicable only for keratinizing (WHO type I) and non-keratinizing (WHO type II) carcinoma. Other malignant tumors of nasopharynx, such as adenoid cystic carcinoma, lymphoma and plasmacytoma, should refer to respective guidelines for optimal management. In Taiwan and other Asian country, keratinizing carcinoma accounts for less than 2% of all NPC. The non-keratinizing carcinoma could be further classified into 2 subtypes: differentiated (II-a) and undifferentiated (II-b). The differentiation/histology grades for WHO type I, II-a and II-b are moderately differentiated (grade 2), poorly differentiated (grade 3) and undifferentiated (grade 4), respectively. The outcome of WHO type II-a and II-b are similar. The radiosensitivity and outcome of WHO type I is believed to be somewhat inferior to that of WHO type II. The management of NPC, however, is basically the same for all these 3 subtypes.

TNM Stage and Taipei VGH Risk Group

The UICC/AJCC TNM staging system, 7th edition of 2010 is used in order to report and compare the results. There are some ambiguous definition or gray area of the 6th TNM that may incur different interpretation and hence inconsistent staging. Supplemental definitions are thus defined by the panel member for consistent staging for NPC (See Taipei VGH Supplement for TNM system of NPC). Of the Taipei VGH supplement to NPC TNM staging, there are 4 major amendments: 1) Measurement of size of lymphadenopathy by MR and/or CT, not by physical examination. 2) Measurement of confluent lymphadenopathy for reporting size of lymphadenopathy. 3) Definition of lymphadenopathy at T1 or below the transverse vein as supraclavicular lymphadenopathy (N3b).

Management by Taipei VGH Risk Group

Most institutes use TNM stage grouping for treatment planning. There are some minor deficiencies of the 7th/**8th** TNM system, which may not reflect the true prognosis of an individual patients. The deficiencies of the existing TNM include: 1) No T2-3 definition between T1 oropharyngeal invasion and T4 for hypopharyngeal invasion. 2) A jump from N1 to N3 for unilateral lymphadenopathy at cut-off lymph node size of 6cm. 3) No definition of T category for parotid invasion. 4) No definition of N category for pre-auricular and peri-parotid lymphadenopathy. And 5) Suboptimal stage grouping for reflecting prognosis. In the 8th TNM, there is a jump of T category from T2 of adjacent muscle invasion to T4 of infiltration beyond the lateral surface of pterygoid muscles

For optimal management, the NPC panel members use additional criteria to define Taipei VGH NPC Risk Groups for decision making.

Manuscript (II)

In this practice guidelines, the NPC panel members recommend treatment of choice based on Taipei VGH risk group. Because TNM stage and Taipei VGH Risk Group are classified by pre-defined cut-off values, there is inevitably variation of prognosis within a stage group or risk group. As a result, the NPC panel members also provide alternative treatment plans for each risk group. The NPC panel members strongly recommend that the treatment of choice for risk group be performed whenever feasible. The alternative treatments could be offered to the patient only when the treatment of choice is refused by the patient, or when NPC team member, by their own independent medical judgment to the context of individual patient's clinical circumstance and sub-TNM grouping, to perform a customized care.

In addition, cancer patients are encouraged to participate in a clinical trial for the best management care.

Radiation therapy is the mainstay of the treatment for localized nasopharyngeal cancer with 8th TNM stage I to IV-A.

Combined radiation therapy and chemotherapy are indicated for medically-fit NPC patients of stage T1-2N1M0, stage III, and stage IV-A disease. Radiotherapy alone is indicated for patients who are not medically fit for aggressive combined chemotherapy.

Patients with distant metastases at presentation should receive chemotherapy first, followed by radiotherapy with standard or reduced dose to the primary tumor and draining lymphatic regions. For patients with metastatic NPC having partial or complete response after primary chemotherapy, locoregional radiotherapy added to chemotherapy significantly improved OS (JAMA 2020).

There is no so-called standard chemotherapy regimen for NPC. Most regimens for NPC are Cisplatin-based with or without 5FU. Cisplatin and Gemcitabine has been reported to be a very effective induction chemotherapy (NEJM 2019).

Target therapy with anti-EGF Cetuximab can be considered in patients with poor renal function or intolerance to Cisplatin-based chemotherapy.

The overall survival rates of NPC has been greatly improved through out the 4 era: 1) 1971-1985 Cobalt-SSD; 2) 1986-1995 2D-Linac-SAD; 3) 1996-2002 3D Conformal Radiotherapy. and 4) IMRT and CCRT (*Table*, *Graph*).

The good survival data in the IMRT-CCRT era at Taipei VGH, better than the pooled survival data of peer medical centers in Taiwan published online by MOWH-HPA, validates the effectiveness of this guideline.

Manuscript – Principles of Radiation Therapy (I)

Treatment Preparation

All patients should have pre-radiation therapy dental evaluation and dietitian consultation. The patient is set up for simulation and RT in a supine position with head extended and immobilized by a customized thermoplastic mask Special attention and measures should be made to ensure the preproduction of shoulder and neck position through out the course of RT.

CT Simulation

CT image provides electron density for tissue heterogeneity correction of radiation dose computation. CT simulation with 3-5 mm slide thickness should be taken prior to 3D-CRT or IMRT planning. For optimal digital reconstructed radiograph (DRR) rendering, a 3mm slide thickness of CT simulation is preferred.

Adaptive CT simulation at around 40 Gy is recommended for optimal planning of the for the last 20Gy radiation therapy.

Target Delineation

MRI is the imaging modality of choice for diagnostic workup of NPC for its high tissue contrast. (Chong 1996, Gong 1991, Ng 1997). The pulse sequence of MRI should include pre-contrast T1 without fat saturation series and post-contrast with fat saturation series. Ng et al. reported a significantly higher detection rate by MRI versus CT for intracranial extension (57% vs. 36%), skull base involvement (60% vs. 40%), retropharyngeal node (58% vs. 21%), and prevertebral muscle infiltration (51% vs. 22%)3. To exploit the superior sensitivity, image fusion of diagnostic MR to simulation CT is recommended for precise gross target volume (GTV) delineation and optimal treatment planning (Emami 2003). If image fusion with diagnostic MRI and/or PET is not available for RT planning, both non-contrast and contrast CT simulation should be performed for optimal target delineation.

The common radiologic criteria for defining a lymph node as metastatic include the presence of central necrosis or extranodal extension (***ENE***, or exptracapsular spread), shortest axial diameter ≥10 mm (11 mm for jugulodigastric node and 5 mm for retropharyngeal node), or group of three of more contiguous lymph nodes that are borderline in size (Van den Brekel 1990).

NPC is both radiosensitive and chemosensitive. The gross tumor volume could have dramatically shrinkage during the course of radiation therapy. The body surface contour could also be changed by tumor shrinkage and weight loss secondary to toxicity. These could potentially affect the tumor control rate and increase complication. It is thus recommended that a second CT simulation be taken for adaptive re-planning of the last 20-30Gy RT.

Target Volume

The report and documentation of various target volumes, such as Gross Tumor Volume (GTV), Clinical Target Volume (CTV), and Planning Target Volume (PTV) should follow the definitions in report 50 and report 62 from the International Commission of Radiation Units and Measurement (ICRU). The practice guideline, “Basic Common Items of Radiation Therapy Summary Report Version 2009”, of Taiwan Society for Therapeutic Radiology and Oncology (TASTR0) recommends to report external beam radiotherapy by dose levels: ***CTV_H***, ***CTV_M*** and ***CTV_L*** for high, mid and low dose levels, respectively, corresponding to the tumor burden. The description and naming of neck lymphatic station included in the various CTVs should follow the consensus of the intergroup guideline (Gregoire 2003)

The external beam radiotherapy for NPC is usually given to two or three dose-level of CTVs. Different centers may have different philosophies in defining the CTV_H, CTV_M, and CTV_L in NPC. There is no level I evidence in regard to the delineation of optimal treatment volume. The following recommendations are consensus-based:

The CTV_H consists at least GTV of both primary tumor and lymphadenopathy (LAP). Some centers may include a margin of 3-5mm around GTV and/or whole nasopharynx in CTV_H. Any identifiable ENE around gross lymphadenopathy should be included in CTV_H.

The CTV_M usually consists of the following structures: 1) CTV_H plus 3-mm to 5-mm margins (2-mm or less margin near the critical structures such as brain stem); 2) Whole nasopharynx; 3) Parapharyngeal space and retropharyngeal lymph nodes: 4) pterygopalatine fossa, 5) posterior wall of maxillary sinus; 6) the adjacent skull base and foramen; 7) bilateral level II lymph node stations; and 8) the lymph node station of the gross metastatic lymphadenopathy. Paravertebral muscles, sternocleidomastoid muscles and inferior lateral portion of the medial pterygoid muscle without gross tumor invasion and/or infiltration can be excluded from CTV_M.

The CTV_L usually consists of distant neck lymphatic station, down to bilateral level IV, without gross metastatic lymphadenopathy. Level Ib without gross lymphadenopathy can usually be spared. In case of association with large >3cm level IIA lymphadenopathy, level IB could be electively included in either CTV_M or CTV_L. Supraclavicular fossa (SCF) was usually irradiated in the 2D era. For level II LAP+ only NPC, SCF could be optionally spared. For N0 disease, level IV could be optionally spared.

The PTV covers the CTV with additional uncertainty margin needed for systemic and random setup variations. Individual centers may have different uncertainty margin for PTV in their actual practice. With proper immobilization and meticulous care in setup, an expansion margin of 3 mm is usually adequate for the primary tumor region. The uncertainty margin for neck lymphatic region is 3-5mm or even more. With the introduction of image guided radiation therapy delivery (IIGRT or IGRTD), the uncertainty margin may be reduced to 2mm. Per recommendation of ICRU report 62, the margin near critical structures can be reduced to avoid late complication.

Manuscript – Principles of Radiation Therapy (II)

Dose, Fractionation and Time

Based on the retrospective 2D-RT data, the most common prescribed total dose of external beam RT to gross tumor (CTV_H) of NPC is 66 to 72 Gy given in 1.8Gy to 2 Gy per fraction, 5 fractions per week, over a period of 6 to 8 weeks. The recommended total doses for elective treatment of subclinical disease (CTV_M and CTV_L) is around 50-60Gy.

A total dose of 70Gy in 7 weeks in the 2D-RT era could adequately control T1-T2 tumor. The control rate of T3-T4 with 70Gy or more given by 2D-RT is less than 55% (Perez 1992). The control rate of T3-T4 has been dramatically improved to >90% by 70Gy of IMRT with or without concurrent chemotherapy.

Before the era of IMRT, the dose per fraction for gross tumor (CTV_H) and subclinical disease (CTV_M and/or CTV_L) were the same and the whole cycle of RT was usually given in 2 phases: Phase 1 with initial large fields to cover both the gross tumor and the subclinical disease up to 45 to 54Gy, followed by Phase 2 with coned down fields to boost the gross tumor up to the 66Gy~70Gy or more.

In the era of IMRT, simultaneous integrated boost (SIB) becomes technically feasible and gains popularity with its potential radiobiological benefit: 1) Increased tumor cell killing with high-dose 2 to 2.4Gy per fraction for CTV_H, and 1) Reduced normal tissue side effects with low-dose 1.6 to 1.9Gy per fraction for CTV_M and CTV_L. Different centers have various schemes of dose per fraction for SIB-IMRT. The consensus of this panel is to include the GTV only in the CTV_H in case of applying extra high-dose 2.1Gy-2.4Gy per fraction in SIB-IMRT. It is also a consensus to avoid dose per fraction below 1.7Gy to treat CTV_M and/or below 1.6Gy to treat CTV_L in SIB-IMRT.

For large residual lymphadenopathy presented at the end of the 70Gy, a focal boost dose of fractionated 4-10Gy can be given at the discretion of radiation oncologist, as an alternative to neck dissection.

For large T4 intracranial invasion, hyperfractionated RT with 1.2Gy per fraction and 2 fractions per day up to a total dose of 72Gy to 75.6Gy can be applied to decrease the risk of late complication (Wolden 2003).

Various accelerated fractions schemes were tested in non-randomized studies in 2D-RT era. The rate of temporal necrosis was found to increased with 1.6Gy per fractions, 2 fractions per day (Leung 1992, Jen 2001)

External Beam Treatment Planning and Irradiation Technique

Compared to 2D RT, 3D conformal RT improves tumor coverage (Leibel), increases local control rate and reduces xerostomia (Yen). Dosimetry studies in various centers have concluded that the conformity of radiation dose distribution to target volume of NPC can be further improved by Intensity modulated radiation therapy (IMRT) (Hunt, Kam, Xia). IMRT is thus the radiation technique of choice for NPC. There are various forms of IMRT, including step-and-shoot, sliding windows, intensity modulated arc therapy (IMAT), and tomotherapy. There is no prospective study to compare locoregional tumor control rate among these IMRT techniques.

Plan approval and normal tissue dose constraint

Dose volume histogram (DVH) is the basic and most important tool for plan assessment and approval. There is no level I evidence in regard to plan approval criteria for PTV and CTV. The ideal approval criteria for CTV and its associated PTV is 1) 100% of CTV and 95% PTV receiving at least the corresponding prescribed dose level, and 2) 100% of PTV receiving at least 95% of the corresponding prescribed dose level. By discretion of radiation oncologist, the approval criteria could be loosen in case of PTV overlapping with critical structures or PTV flushing outside body for superficial large lymphadenopathy. For CTV_H and PTV_H, the maximum dose should be kept below 115% of the prescribed isodose and less than 10% of PTV_H receiving 110% or more of the prescribed dose.

The common dose constraints to critical structures are listed as the followings:

Normal Tissue	**Ideal Criteria**	**Acceptable Criteria**
Brain Stem	*<54Gy*	*1ml or less < 60Gy*
Spinal Cord	*<45Gy*	*1ml or less < 50Gy*
Parotid Gland	*mean < 26Gy*	*mean dose < 35Gy*
Lens	*< 6Gy*	*<10Gy*
Optic nerve	*<50Gy*	*<56Gy*
Temporal Lobe	*< 56Gy*	*1% < 63Gy*

Brachytherapy

Several retrospective studies showed that intra-cavity brachytherapy boost improved primary tumor control rate for T1-T2 NPC for 2D external beam RT (Wang 1991, Teo 2000). Its benefit in the era of IMRT and concurrent chemotherapy is unknown.

Integration of Systemic Therapy

- **Following the induction chemotherapy, CCRT should be given instead of radiotherapy alone to combat possible accelerated repopulation.**
- **CT simulation for RT should be arranged 2 weeks in advance before the start of RT, so that the CCRT could be performed as on week 7-9 (T1-3) or week 10-13 (T4).**

Charged Particle Therapy – Proton Therapy

- **The biological effectiveness of proton therapy is similar to photon beam with average RBE about 1.1. The prescribed RBE dose of proton therapy is the same as photon beam.**
- **Theoretically, proton therapy can achieve similar local tumor control rate with reduced complication of the surrounding normal tissue in certain critical tumor extension, such as skull base invasion, compared to conventional IMRT.**
- **Nonrandomized institutional reports and limited systematic reviews have shown that PBT is safe to use in a controlled setting. However, there is no high-quality prospective study to conclude that proton therapy is superior to IMRT with regard to tumor control.**
- **Robust planning is recommended for *range uncertainty issue in Bragg Peak irradiation*.**
- **Timely adaptive simulation and planning should be performed to ensure accurate dose delivery in the presence of body shape change or marked tumor shrinkage during the radiation course.**

Charged Particle Therapy – Carbon Ion Therapy (CIT)

- **CIT has superior physical dose distribution advantage of Bragg Peak than photon therapy.**
- **CIT, with dense ionization track for effective DNA direct double strain break, has biological advantage of *high RBE* (RadioBiological Effectiveness) and *low OER* (Oxygen Enhancement Ratio) over both proton and photon therapy.**
  - CIT is theoretically more effective in radioresistant cancer, such as melanoma, adenoid cystic carcinoma or chondrosarcoma, than proton or photon therapy.
  - CIS is theoretically more effective in cancer with high hypoxic fraction, or in hypofractionated setting/radiosurgery where hypoxic cells would significantly counter the radiobiological effectiveness of proton and photon therapy.
- **With high RBE and potential normal tissue damage, CIT is currently not suitable in the following scenarios:**
  - Post-operative irradiation
  - Elective irradiation of subclinical target volume in definitive RT.
- **CIT is not indicated as the first line radiation modality in high radiosensitive cancers, such in the case of NPC, lymphoma and etc.**
- **CIT can be used as a upfront boost for radio-resistant Head and Neck cancers, such as mucosal melanoma, adenoid cystic carcinoma, sarcomas, verrucous carcinoma, and or epidermoid carcinoma.**
  - For example, upfront CIT boost 18~20Gy/4~5 fractions to GTV + IMRT 45~50Gy/25 fractions to CTV of Subclinical Disease surrounding/extending outside the GTV
  - COSMIC Phase II Trial for Malignant Salivary Gland Tumor CIT Boost 24GyE/8 fractions + IMRT 50Gy/25 fractions

Boron Neutron Capture Therapy (BNCT)

- **BNCT can be used as a salvage radiation modality for superficial (<7cm in depth) locally recurrent head and neck cancers with high BPA (Boron-Phenylalanine).**
- **For nasal cavity/paranasal sinus mucosal melanoma, BNCT combined with IMRT can be used as the definitive treatment, provided that the patient is not medically fit for surgery.**

NPC Overall Age-Adjusted Overall Survival Data in Taiwan

with last FU date 20201231, published by DHP/MOHW on 20210826









Taipei VGH NPC 2010~2017 Unadjusted Overall Survival By AJCC Stage with last FU date 20201231, published by DHP/MOHW on 20210826

2010~2017 Taipei VGH Unadjusted Overall Survival: Nasopharynx by AJCC Stage

Number at Risk	527	43	72	194	165	53
Dead	112	3	6	26	42	35
Year	Stage All	Stage I	Stage II	Stage III	Stage IV M0	Stage IV M1
1	*94.31*	*100*	*97.22*	*98.97*	*94.55*	*67.92*
2	*88.8*	*95.35*	*97.22*	*95.36*	*88.48*	*49.06*
3	*84.44*	*95.35*	*94.44*	*91.75*	*83.03*	*39.62*
4	*81.03*	*95.35*	*91.65*	*90.11*	*77.09*	*33.96*
5	*77.98*	*92.77*	*91.65*	*85.69*	*73.09*	*33.96*

Data Source: Heath Promotion Administration, MOWH, Taiwan - 癌症醫療品質管理考核資訊系統; downloaded on 20210826

Taiwan NPC 2010~2017

Age-Adjusted 5-Year Overall Survival Data (%)

with last FU date 20201231, published by DHP/MOHW on 20210826

醫院層級		第1期	第2期	第3期	第4M0期	第4M1期	第4期	不分期別
北榮	個案總數	43	72	194	165	53	218	527
	已死亡數	3	6	26	42	35	77	112
	設限總數	4	13	42	38	6	44	103
	>5Y存活個案數	36	53	126	85	12	97	312
	5Y-CSS %	93.11	91.95	85.5	73.42	35.41	64.38	78.41
	95% CI	85.95 100	81.95 100	74.35 96.64	60.62 86.22	18.56 52.26	52.25 76.52	70.82 86
	MST (mo)	NR	NR	NR	NR	23.2	104.8	NR
醫中	5Y-CSS %	88.3	86.82	78.96	63.37	15.1	54.34	71.43
	95% CI	83.11 93.5	83.04 90.6	75.35 82.56	59.22 67.52	9.07 21.13	50.55 58.12	69.22 73.64
	vs VGH p=	0.2948	0.4052	0.2738	0.1432	0.0261	0.1212	0.0835
	MST (mo)	NR	NR	NR	114.9	15.75	79.3	NR
非醫中	5Y-CSS %	90.58	83.18	74.21	58.03	15.16	48.9	68.22
	95% CI	84.17 96.99	77.72 88.64	69.38 79.03	51.98 64.09	6.8 23.51	43.58 54.22	65.16 71.27
	vs VGH p=	0.6216	0.1475	0.0684	0.0332	0.0348	0.0220	0.0146
	MST (mo)	NR	NR	NR	89.7	15.7	56.5	NR
全國	5Y-CSS %	88.97	85.77	77.2	61.93	15.26	52.84	70.45
	95% CI	84.84 93.11	82.63 88.91	74.28 80.12	58.48 65.38	10.32 20.19	49.73 55.95	68.65 72.26
	vs VGH p=	0.3362	0.2857	0.1582	0.0894	0.0245	0.0709	0.0457
	MST (mo)	NR	NR	NR	108.6	15.6	73.6	NR

1. 數據下載日期 20210901
2. 結腸癌、直腸癌AJCC期別版本8，個案年度2010~8；其餘癌症AJCC期別版本7，個案年度2010~7
3. 子宮頸癌、子宮體癌及卵巢癌FIGO Stage 個案年度2010~8

NPC Overall Age-Adjusted Cancer-Specific Survival Data in Taiwan

with last FU date 20201231, published by DHP/MOHW on 20210826









Taipei VGH NPC 2010~2017 Unadjusted Cancer-Specific Survival By AJCC Stage
with last FU date 20201231, published by DHP/MOHW on 20210826

2010~2017 Taipei VGH Unadjusted Cancer-Specific Survival: Nasopharynx by AJCC Stage

Number at Risk	527	43	72	194	165	53
Dead	91	0	2	19	36	34

Year	Stage All	Stage I	Stage II	Stage III	Stage IV M0	Stage IV M1
1	*95.23*	*100*	*100*	*98.97*	*96.34*	*67.92*
2	*90.61*	*100*	*100*	*96.38*	*90.16*	*50.5*
3	*86.91*	*100*	*98.55*	*93.75*	*85.22*	*40.79*
4	*84.22*	*100*	*97.1*	*92.6*	*80.5*	*34.96*
5	*81.79*	*100*	*97.1*	*89.42*	*76.32*	*34.96*

Data Source: Heath Promotion Administration, MOWH, Taiwan - 癌症醫療品質管理考核資訊系統; downloaded on 20210826

Taiwan NPC 2010~2017

Age-Adjusted 5-Year Cancer-Specific Survival Data (%)

with last FU date 20201231, published by DHP/MOHW on 20210826

醫院層級		第1期	第2期	第3期	第4M0期	第4M1期	第4期	不分期別
北榮	個案總數	43	72	194	165	53	218	527
	已死亡數	0	2	19	36	34	70	91
	設限總數	7	17	49	44	7	51	124
	>5Y存活個案數	36	53	126	85	12	97	312
	5Y-CSS %	100	97.55	89.28	76.51	35.98	66.8	82.09
	95% CI	100 100	92.92 100	79.32 99.25	63.84 89.18	18.72 53.23	54.55 79.06	74.91 89.28
	MST (mo)	NR	NR	NR	NR	27.1	NR	NR
醫中	5Y-CSS %	95.33	90.45	83.19	68.61	17.85	59.36	76.29
	95% CI	91.66 99	87.02 93.88	79.69 86.69	64.42 72.81	10.99 24.71	55.45 63.27	74.12 78.46
	vs VGH p=	0.0126	0.0169	0.2580	0.2463	0.0557	0.2566	0.1295
	MST (mo)	NR	NR	NR	NR	17	128.4	NR
非醫中	5Y-CSS %	95.56	87.31	79.02	62.15	18.44	53.23	72.92
	95% CI	91.33 99.79	82.16 92.46	74.2 83.84	55.96 68.35	8.74 28.13	47.7 58.76	69.87 75.97
	vs VGH p=	0.0397	0.0041	0.0691	0.0460	0.0824	0.0478	0.0212
	MST (mo)	NR	NR	NR	NR	16.9	79.6	NR
全國	5Y-CSS %	95.24	89.51	81.67	66.82	18.28	57.62	75.21
	95% CI	92.22 98.26	86.62 92.4	78.81 84.53	63.31 70.32	12.64 23.93	54.39 60.84	73.43 77
	vs VGH p=	0.0020	0.0029	0.1500	0.1483	0.0562	0.1552	0.0685
	MST (mo)	NR	NR	NR	NR	16.9	116.3	NR

NPC Taipei VGH 2010-2017 Overall Survival Curves by AJCC Stage; Data updated on *20200423* (n=537)



5-Year Overall Survival Rate and Median Survival Time of Non-Metastatic NPC at Taipei VGH by Different Treatment Era

TNM Stage	1971~1985 SSD Cobalt	1986~1995 SAD Linac	1996~2002 3D-CRT	2010~2017 IMRT-CCRT (*20210826*)
I	83.7% / 12.9Y	78.1% / 14.1Y	88.7% / -	92.8%
II	55.6% / 6.9Y	61.7% / 9.4Y	78.3% / -	91.7%
III	35.4% / 2.8Y	53.9% / 6.9Y	66.6% / -	85.7%
IVa-b	27.7% / 2.0Y	38.7% / 2.7Y	52.1% / 5.9Y	73.1%
All	42.2% / 3.5Y	54.2% / 6.1Y	68.6% / -	78%

** 2010~7 5 Stage I patients died. Only one of these 5 patients died of recurrent NPC.*
** 2010~7 5-Y overall survival rate for M1 disease: 34%*

Taipei VGH NPC Survival Curves: M0









References

Imaging, Staging and Prognostic Factors

1. King AD, Ahuja AT, Leung SF, et al. Neck node metastases from nasopharryngeal carcinoma: MR imaging of pattern of disease. Head Neck 2000; 22: 275–281
2. Lam WM, Chan YL, Leung SF Metreweli C. Retropharyngeal lymphadenopathy in nasopharyngeal carcinoma. Head lymph node from multiple matted nodes. Head Neck 1997; 19: 176–181
3. Ng SH, Chang TC, Chan SC, et al. Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. Eur J Nucl Med Mol Imaging 2004; 31:1073–1080
4. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer Stage III and IV nasopharyngeal cancer of the endemic variety. JCO 2005; 23:6730-6738.
5. Chong VF, Fan YF, Khoo JB. Nasopharyngeal carcinoma with intracranial spread: CT and MR characteristics. J Comput Assist Tomogr 1996;20:563–569.
6. Gong QY, Zheng GL, Zhu HY. MRI differentiation of recurrent nasopharyngeal carcinoma from postradiation fibrosis. Comput Med Imaging Graph 1991;15:423–429.
7. Ng SH, Chang TC, Ko SF, et al. Nasopharyngeal carcinoma: MRI and CT assessment. Neuroradiology 1997;39:741–746.
8. Emami B, Sethi A, Petruzzelli GJ. Influence of MRI on target volume delineation and IMRT planning in nasopharyngeal carcinoma. IJROBP 2003;57:481–488.
9. Van Den Brekel MWM, Stel HV, Castelijns JA. Cervical lymph node metastasis: Assessment of radiologic criteria. Radiology 1990;177:379–384.
10. Perez CA, Devineni VR, Marcial-Vega V, et al. Carcinoma of the nasopharynx: Factors affecting prognosis. IJROBP 1992;23:271–280.
11. Grégoire V, Levendag P, Ang KK, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol. 2003 Dec;69(3):227-36.
12. Lin TY, Lan MY, Tsou HH, Ho CY, Twu CW, Liu YC, Lin PJ, Huang PI, Shiau CY, Lin JC. Survival impacts of different nodal characteristics and T-classification in N3 nasopharyngeal carcinoma patients. Oral Oncol. 2020 Jun 9;108:104820. doi: 10.1016/j.oraloncology.2020

Target Volume Delineation and Radiation Therapy Planning

1. ICRU Report 50: Prescribing, Recording and Reporting Photon Beam Therapy. ICRU 1993.
2. ICRU Report 62: Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50). ICRU 1999.
3. TASTRO Practice Guideline: Basic Common Items of Radiation Therapy Summary Report Version 2009 (台灣放射腫瘤學會業務執行指引: 放射治療摘要報告通用基本項目)
4. Cheng MC, Hu YW, Shiau CY, et al. Optimal beam design on intensity-modulated radiation therapy with simultaneous integrated boost in nasopharyngeal cancer. Med Dosim. 2014;39(3):246-50
5. Leibel SA, Kutcher GJ, Harrison LB, et al. Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx. IJROBP 1991;20:823–833
6. Jen YM, Shih R, Lin YS. Parotid gland-sparing 3-D conformal radiotherapy results in less severe dry mouth in nasopharyngeal cancer patients: A dosimetric and clinical comparison with conventional radiotherapy. Radiother Oncol 2005;75:204–209.
7. Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. IJROBP 2001;49:623–632.
8. Kam MK, Chau RM, Suen J, et al. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: Dosimetric advantage over conventional plans and feasibility of dose escalation. IJROBP 2003;56:145–157.
9. Xia P, Fu KK, Wong GW, et al. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. IJROBP 2000;48:329–337
10. Teo PM, Leung SF, Lee WY, et al. Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: The existence of a dose-tumor-control relationship above conventional tumoricidal dose. IJROBP 2000;46:445–458.
11. Wang CC. Improved local control of nasopharyngeal carcinoma after intracavitary brachytherapy boost. Am JCO 1991;14:5–8.

References

Systemic Therapy

1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. JCO 1998; 16:1310-1317
2. Langendijk JA, Leemans CR, Buter J, Berkhof J, and Slotman BJ. The Additional Value of Chemotherapy to Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of the Published Literature. JCO 2004; 23:1118-1124
3. Wolden SL, Zelefsky MJ, Kraus DH, et al. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. JCO 2001;19:1105–1110.
4. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. JCO 2005; 23:3568-3576.
5. Lee AW, Lau WH, Tung SY, et al. Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. JCO 2005; 23:6966-6975
6. Leong SS, Wee J, Tay MH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer 2005; 103:569-575.
7. Chua DT, Ma J, Sham JS, Mai HQ, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. JCO 2005 Feb 20;23(6):1118-24
8. Twu CW, Wang WY, Chen CC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. IJROBP 2014; 89(1): 21-29.
9. Sun Y, Li WF, Chen NY, Zhang N, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-1520
10. Liu YC, Wang WY, Lin JC, et al. Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. Oral Oncol. 2017 Jan;64:15-21
11. Ribassin-Majed L, Marguet S, Lee AWM, et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. JCO 2017 Feb 10;35(5):498-505
12. Chen L, Hu CS, Chen XZ, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017 Apr;75:150-158
13. Tan TH, Soon YY, Cheo T, et al.. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis. Radiother Oncol. 2018 Oct;129(1):10-17
14. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Hong RL, Hsiao CF, Ting LL, et al. Ann Oncol. 2018 Sep 1;29(9):1972-1979.
15. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. NEJM 2019 May 31
16. Chen JH, Huang WY, Ho CL, Chao TY, Lee JC. Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. Head Neck. 2019 Nov;41(11):3775-3782

Survival Data and Complications

1. Jen YM, Hsu WL, Chen CY, et al. Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques. IJROBP 2001;51:344–348.
2. Leung SF, Kreel L, Tsao SY. Asymptomatic temporal lobe injury after radiotherapy for nasopharyngeal carcinoma: Incidence and determinants. Br J Radiol 1992;65:710–714.
3. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Jul 23. doi: 10.1001/jamaoncol.2020.1808.
4. 衛生福利部國民健康署全國管考系統: 2010/06/08公布 20120-2017年齡調整五年整體存活率